Conference Description:

The 5th Inflammasome Therapeutics Summit returns to Boston to unite industry pioneers at a critical time as clinical readouts are expected, and a wave of new collaborations hit the headlines.

As we focus on more inflammasomes beyond NLRP3, they are becoming prominent as potential targets for treating inflammation with drugs. This is a chance for you to join forces with like-minded individuals who prioritize inflammasome therapeutics.

Together, we can address important aspects such as discovery science and mechanisms, overcoming challenges related to biomarkers, selecting the right diseases to target, and making progress in developing preclinical models.

This is the largest gathering of inflammasome biopharma experts and pioneers set to advance inflammasome inhibitors and activators from the pipeline to in-human efficacy.

Gathering industry super giants, including NodThera, Novartis, Roche, Ventus, AC Immune, and more, this is your chance to join forces with 100+ inflammasome pioneers for interactive discussions.

URL:
Tickets: https://go.evvnt.com/1883998-2?pid=154
Time: 8:00 am - 5:00 pm

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 3296.00,
Drug Developer Pricing - Conference Only: USD 2099.00,
Solution Provider Pricing - Conference + Workshop Day: USD 4296.00,
Solution Provider Pricing - Conference Only: USD 2799.00,
Academic and Not for Profit - Conference + Workshop Day: USD 2596.00,
Academic and Not for Profit - Conference Only: USD 1699.00

Speakers: Alan Watt, Chief Executive Officer, NodThera, Ali Jazayeri, Chief Scientific Officer, OMass Therapeutics, Andrew Placzek, Principal Scientist, Schrodinger, Anick Auger, Head of In Vitro and In Vivo Pharmacology, Ventus Therapeutics, Ashley Mansell, Head of Translational Science, Adiso Therapeutics, Danaelle Capron, Antibody Discovery Scientist, Mabylon, Daniel Bachovchin, Assistant Member, Memorial Sloan Kettering Cancer Center, Davide Basco, Senior Scientist and Project Leader, AC Immune, David Bearss, Chief Executive Officer, Halia Therapeutics, Deven Parmar, Chief Medical Officer Zydus, Therapeutics, Eric Prinsenn, Senior Neuroscientist and Project Leader, Roche, Hao Wu, Professor - Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harold Hoffman, Professor and Chief of Allergy, Immunology, and Rheumatology, University of California San Diego, Jonathan Kagan, Professor Harvard Medical School Co-Founder, Corner Therapeutics, Juan Pablo, de Rivero Vaccari Associate Professor, University of Miami, Kate Schroder, Head of Laboratroy, University of Queensland, Marc Pelletier, Associate Director - Translational Immune Oncology, Novartis, Marianna Rowlands, Translational Medicine Development and Immunology Therapeutic Area Biomarker Lead, Novartis, Rusty Montgomery, Vice President - Biology, BioAge Labs, Seung-Yong Seong, Chief Executive Officer, Shaperon, Thirumala-Devi Kanneganti, Professor, St. Jude Children's Research Hospital, Tony Reid, Chief Executive and Scientific Officer, EpicentRx